LONDON, England / ACCESSWIRE / August 5, 2014 / GW Pharmaceuticals plc (NASDAQ: GWPH) will host a live webcast to discuss the results of the third quarter 2014, to be held Wednesday, August 6, 2014 at 8:00 AM Eastern Time.
You may listen to the event online at www.investorcalendar.com/IC/CEPage.asp?ID=173050 as well as via the GW Pharmaceuticals website (www.gwpharm.com).
If you are unable to participate during the live webcast, the event archive will be available at www.investorcalendar.com/ClientPage.asp?ID=173050 or www.gwpharm.com.
About GW Pharmaceuticals
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex(R), which is approved for the treatment of spasticity due to multiple sclerosis in 25 countries outside the United States. Sativex is also in Phase 3 clinical development as a potential treatment of pain in people with advanced cancer. This Phase 3 program is intended to support the submission of a New Drug Application for Sativex in cancer pain with the U.S. Food and Drug Administration and in other markets around the world. GW has a deep pipeline of additional cannabinoid product candidates, including Epidiolex which has received from the FDA Fast Track Designation for the treatment of Dravet syndrome and Orphan Drug Designation from the FDA for the treatment of Dravet and Lennox-Gastaut syndromes, severe, drug-resistant epilepsy syndromes. GW's product pipeline also includes compounds in Phase 1 and 2 clinical development for glioma, ulcerative colitis, type-2 diabetes, and schizophrenia. For further information, please visit www.gwpharm.com.
SOURCE: GW Pharmaceuticals